Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects

J Cardiovasc Pharmacol. 1987 Aug;10(2):129-35. doi: 10.1097/00005344-198708000-00001.

Abstract

S-9780 is the active diacid metabolite of the new angiotensin-converting enzyme (ACE) inhibitor perindopril. In a double-blind, randomised, crossover study, the effects of 1, 2, and 4 mg of S-9780 administered intravenously (i.v.) were compared with placebo in eight normotensive subjects. All active doses caused immediate, maximal, and similar inhibition of plasma ACE with 40% inhibition persisting after 48 h. Plasma renin activity was elevated 4 and 8 h after dosing, but no effect on plasma aldosterone, adrenaline or noradrenaline levels was detected. Diastolic blood pressure was lowered by 4 mg of S-9780 until 24 h after dosing. Heart rate did not change. The pharmacokinetics of S-9780 fitted a three-compartment model with a terminal half-life (t1/2) of 31 h. Inhibition of plasma ACE was closely related to observed drug concentration, with 1.8 +/- 0.9 ng/ml (mean +/- S.D.) producing 50% inhibition of the enzyme. S-9780 caused predictable effects on the cardiovascular and renin angiotensin systems.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aldosterone / blood
  • Angiotensin-Converting Enzyme Inhibitors*
  • Blood Pressure / drug effects
  • Catecholamines / blood
  • Double-Blind Method
  • Female
  • Heart Rate / drug effects
  • Humans
  • Indoles / pharmacology*
  • Kinetics
  • Male
  • Perindopril
  • Random Allocation
  • Renin / blood

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Catecholamines
  • Indoles
  • perindoprilat
  • Aldosterone
  • Renin
  • Perindopril